Shop Antibodies
Best Seller

Transgenic Antibody Production

$4,950.00

Item Cat No.: BCFTIG

Antibody: Monoclonal Antibody

Concentration: 0.25 mg/ml purified IgG

Application: In Vitro and In Vivo

Reactivity: Human, Mouse, Rat

BiCell Scientific’s transgenic antibody production service provides customized recombinant monoclonal antibody expression and purification in naive B cell hybridomas.

Recombinant monoclonal antibodies were previously cloned into mammalian expression vectors, such as pcDNA3.1  and transiently transfected into HEK293 or COS cells for transgenic expression.

This approach has two disadvantages – (1) HEK293 cells and COS cells are surrogate cell models that lack endogenous antibody production and secretion machinery as in native B cells; (2) Transient transfection lacks the ability to make stable cell lines that can continuously secrete IgG molecules over many generations of cell culture.

BiCell Scientific’s transgenic antibody production service harnesses the advantageous lentiviral transduction ability to simultaneously express IgG heavy chain and light chain at a molecular ratio of 1:1 in naive B cell hybridomas. The resultant B cell hybridomas can produce recombinant antibodies at a similar level to native B cell-myeloma fused hybridomas. The resultant recombinant antibodies undergo similar assembly and modification processes to native antibody proteins.

  • Molecular cloning of IgG heavy chain and light chain sequences into lentiviral backbone vector
  • Transfection of HEK293T cells with lentiviral backbone vector as well as vectors expressing gagpol, rev and vsvg
  • Harvesting and purification of lentivirus from cell culture medium
  • Transducing naive Sp2/0-Ag14 hybridoma cells
  • Clonal selection and stable cell line establishment in 96-well plate
  • Validation of recombinant antibody expression in 96-well plate and selection of highly expressing clones
  • Clonal expansion and affinity purification of recombinant antibody

Customers will receive the following deliverables at the end of each project:

  • One stable Sp2/0-Ag14 hybridoma cell line expressing recombinant monoclonal antibody with the highest yield
  • 1 mg of affinity purified monoclonal antibody
  • IgG heavy chain and light chain cloning into lentiviral vector – 2-3 weeks
  • Lentivirus packaging  – 1-2 weeks
  • Naive Sp2/0-Ag14 hybridoma cell transduction – 1-2 weeks
  • Clonal selection and stable cell line establishment – 3-4 weeks
  • Recombinant antibody expression validation – 2-3 weeks
  • Cell culture expansion and affinity purification – 2-3 weeks

Reviews

There are no reviews yet.

Be the first to review “Transgenic Antibody Production”

"I am really impressed with your approach. We tried multiple times previously to create monoclonal and polyclonal antibodies to claudin-2 and MLCK1. We have had limited success generating polyclonals and no success generating monoclonals. You have generated outstanding monoclonals to both. I look forward to continuing to work with you."

Jerrold R. Turner, M.D., Ph.D.

Brigham and Women’s Hospital | Harvard Medical School

"The polyclonal antibody you generated for KIAA0408 is stunning! KIAA0408 is a novel cilium molecule that has never been studied. So, clearly there will be a lot of demand for it as we have discovered a very interesting finding and the story will be published in a high impact journal. I am strongly inclined to generate monoclonal antibody for this protein too and we should think about patenting it."

Univ.-Prof. Jay Gopalakrishnan PhD

Heinrich-Heine-Universität | Universitätsklinikum Düsseldorf

"Your ARL13B antibody works beautifully!!! We’re so happy to have a cilia-specific antibody made in rat! I can send you high resolution images to be posted on your website."

Julie Craft Van De Weghe, PhD

School of Medicine | University of Washington

"The assay is a homophilic interaction mediated cell adhesion on purified protein (in this case, immobilized purified Pcdhga9 to Pcdhga9 expressed on cell surface). Compared to control, cell adhesion is reduced in the presence of Pcdhga9 monoclonal antibody supernatants!"

Divyesh Joshi, PhD

School of Medicine | Yale University

Contact us for questions or custom requests!